CVS Health (CVS) Tops Q2 EPS by 36c, Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
CVS Health (CVS) PT Raised to $95 at Cantor Fitzgerald
August 4, 2021 12:48 PM EDTCantor Fitzgerald analyst Steven Halper raised the price target on CVS Health (NYSE: CVS) to $95.00 (from $92.00) while maintaining a Overweight rating following earnings.
The analyst commented, ". We reiterate our Overweight rating on CVS shares and increase our price target to $95 from $92. Before the market open on Wednesday, August... More
